Significant Interaction of MTHFR C677T, A1298C and MTRR A66G Polymorphisms on the Risk of Low Birth Weight Infants

Shuang Sun (✉ sunshuang200816@163.com)

Central Laboratory of Maternal and Child Health Hospital of Jilin Province

Ying Liu

Central Laboratory of Maternal and Child Health Hospital of Jilin Province

Xuehua guo

Central Laboratory of Maternal and Child Health Hospital of Jilin Province

Xun Zhao

Central Laboratory of Maternal and Child Health Hospital of Jilin Province

Research Article

Keywords: MTHFR C677T, MTHFR A1298C, MTRR A66G, Low birth weight

Posted Date: July 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-650493/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: To explore the relationship between maternal methylenetetrahydrofolate reductase (MTHFR) gene C677T and A1298C, Methionine Synthase Reductase (MTRR) gene A66G and the recurrence of low birth weight(LBW) in offspring.

Methods: Allele-specific polymerase chain reaction (ASPCR) assay combined with TaqMan probe technique were used to detect the mother's MTHFR and MTRR genotypes respectively. And unconditional logistic regression analysis was used to evaluate the associations of MTHFR and MTRR polymorphisms, and gene-gene interaction with low birth weight.

Results: MTHFR 677TT and 1298CC were independently associated with a higher risk of LBW (OR:2.22, 95%CI:1.14-4.34 and OR:2.82, 95% CI:1.15-6.87,respectively). The MTRR A66G polymorphism was associated with an significant association of LBW when combined with the MTHFR 677TT genotype, although there was no association found between LBW and MTRR A66G alone. Moreover, two or more risk genotypes carriers showed higher odds of LBW than null risk genotype one.

Conclusion: Maternal MTHFR gene 677TT, 1298CC can increase the risk of LBW in the offspring. The MTRR A66G polymorphism was not associated with LBW alone. But it may exacerbate the effect of the MTHFR C677T variant.

Background

Low birth weight (LBW) is an adverse pregnancy outcome which refers to a baby with a birth weight less than 2 500 g [1]. The incidence of low birth weight infants in China is 5.87% of live births[2]. LBW can lead to a higher mortality rate, and prone to mental retardation and growth retardation[3–4]. Most of the LBW is caused by the combination of environmental and genetic factors. Methylenetetrahydrofolate reductase (MTHFR) and Methionine Synthase Reductase (MTRR) are homocysteine (Hcy) key enzymes of the metabolic pathway, the decreased activity of both may lead to hyperHcyemia[5].

Hyperhomocyticemia is considered to have a toxic effect on the development of the embryo[6]. The level of Hcy in maternal blood is affected by the most common mutation sites of its key enzymes including MTHFR C677T,A1298C and MTRR A66G polymorphism.

MTHFR C677T polymorphism associated with thermolability and reduced enzyme activity, leading to accumulation of Hcy especially under conditions of low dietary folate [7]. MTRR A66G polymorphism decreases the enzyme activity and the rate of Hcy remethylation, and further affects plasma homocysteine levels[8]. MTRR A66G may also induce DNA hypomethylation by regulation of Hcy levels [9]. Moreover, several studies indicated additive or synergistic effects of the MTHFR C677T and MTRR A66G polymorphisms on plasma Hcy levels [10]. MTHFR A1298C is a risk factor for neural tube defects and combined with C677T results in elevated Hcy and decreased plasma folate levels similar to that of 677TT homozygosity [11–13]. Many epidemiological studies have indicated that the MTHFR C677T, A1298C and MTRR A66G polymorphisms with various diseases, including birth defects, pregnancy

complications[14–16].However,whether gene mutations of key enzymes are related to LBW is unclear, we therefore investigated the associations of MTHFR C677T, A1298C MTRR A66G on LBW risk.

Materials And Methods

Subjects

This study enrolled 70 maternal blood samples of premature infants admitted to the Department of Neonatology, Jilin Province Maternal and Child Health Hospital from April 2019 to April 2021 as the case group.70 maternal blood samples of normal births admitted to obstetrics during the same period were selected as the control group.Maternal inclusion criteria: a.No obstetric complications such as eclampsia, diabetes, placenta previa; b.Take multivitamins instead of conventional folic acid during pregnancy. The criteria for selection of low birth weight babies: a. Gestational age > 28 weeks, body weight < 2 500 g; b. Normal delivery, exclude premature babies caused by accidents; c.Eliminate twins or multiple births and congenital malformations. Selection criteria for infants with normal weight: a.Choose the gestational week born in the same hospital > 28 weeks, body weight < 2 500 g, difference in birth time < 7 d, singleton normal live birth infants; b.Excluding pregnant women and pregnant women with complications and complications during pregnancy newborn. Comparing the general data of the two groups, the difference was not statistically significant ($P \geq 0.05$).

DNA Extraction and Genotyping

We extracted DNA from 2 mL whole blood, which was collected in ethylenediaminetetraacetic acid (EDTA) and stored at -20 °C based on provided instructions(Nucleic Acid Extraction and Purification Kit, Kuangyuan Bio., Suzhou, China). Polymorphisms MTHFR C677T, A1298C and MTRR A66G were typed in an allele-specific polymerase chain reaction (ASPCR) assay combined with TaqMan probe technique (Applied Biosystems, Foster City, CA, USA) with the ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA). A sample of the PCR system contained 2 µl of genomic DNA, 22 µl of amplification reagent that included labelled primer pairs (MTHFR gene detection kit; Kuangyuan Bio., Suzhou, China), and 1 µl of reaction solution A (MTHFR gene detection kit; Kuangyuan Bio., Suzhou, China). The positive controls (TT genotype) and negative controls (MTHFR gene detection kit; Kuangyuan Bio., Suzhou, China) were amplified at the same time. The amplification steps were 50°C for 2 min, 95°C for 3 min, and 45 cycles of the following steps: 95°C for 10 s, 56°C for 30 s, and 60°C for 30 s. Fluorescence signal was collected in the last 35 amplification cycles. Finally, the type of MTHFR C677T, A1298C and MTRR A66G genotype was determined according to the number of cycles (CT value) of the fluorescence signal forming the amplification curve at a specific threshold. The main parameters for ASPCR of the three single nucleotide polymorphisms (SNPs) were shown in Table 1.

Table 1
Primer sequences for MTHFR C677T, A1298C and MTRR A66G polymorphisms.

Gene	Primer sequence ¹	Product Size
MTHFR C677T	F: 5'-TGAAGGAGAAGGTGTCTGCGGGA-3' R: 5'-AGGACGGTGCGGTGAGAGTG-3'	198bp
MTHFRA1298C	F: 5'-CTTTGGGGAGCTGAAGGACTACTAC-3' R: 5'-CACTTTGTGACCATTCCGGTTTG-3'	163bp
MTRR A66G	F: 5'-GCAAAGGCCATCGCAGAAGACAT-3' R: 5'-GTGAAGATCTGCAGAAAATCCATGTA-3'	151bp
¹ F: forward primer; R: reverse primer.		

Statistical Analysis

The relationship between MTHFR C677T, A1298C and MTRR A66G polymorphisms and LBW used SPSS v22.0 (IBM, Inc., Armonk, NY, USA) for statistical testing in our study. Quantitative data were expressed as mean $\pm$ standard deviation ($\bar{x} \pm s$) and qualitative data as n (%). Comparisons of difference between the case and control with respect to general characteristics were performed by two-sample t test and Chi-square (χ^2) test, respectively. Unconditional logistic regression analysis was used to evaluate the associations of multi-factors and the three polymorphisms by Odds ratios (OR) and 95% confidence interval (CI). The trend test was used to verify the above results. Hardy-Weinberg equilibrium (HWE) was also assessed for the distributions of genotypes with χ^2 test between cases and controls. A two sided *p* value below 0.05 was considered statistical significance.

Results

Population characteristics

Table 2 summarizes the clinical characteristics of the cases and controls. A total of 106 low birth weight infants were collected, of which 63 were males and 43 were females. The birth weight was (2234.6 ± 275.3) g. There were 165 normal-weight control children, 119 males and 79 females. The birth weight was (3374.7 ± 523.4) g. χ^2 test showed that there were statistically significant in infant birth weight, gestational week of delivery, maternal serum folate level, blood pressure and heart rate between the two groups ($P < 0.05$).

Table 2
Clinical characteristics of case and controls.

Variable	Case(N = 106)	Control(N = 168)	<i>P</i>
	N(%) / $\bar{x} \pm s$	N(%) / $\bar{x} \pm s$	
Maternal age, year	32.37 $\pm$ 10.10	31.38 $\pm$ 9.40	> 0.05
Maternal Height, cm	160.1 $\pm$ 4.8	160.8 $\pm$ 4.1	> 0.05
Prepregnancy weight, kg	53.9 $\pm$ 7.5	55.6 $\pm$ 7.6	> 0.05
Maternal serum folate, nmol/L	12.5 $\pm$ 1.5	16.9 $\pm$ 1.0	< 0.05
SBP, mmHg	128.3 $\pm$ 14.9	117.9 $\pm$ 9.5	< 0.05
DBP, mmHg	84.3 $\pm$ 10.2	79.2 $\pm$ 3.0	< 0.05
FBG, mmol/L	4.88 $\pm$ 1.20	4.92 $\pm$ 0.95	> 0.05
HR, Times/min	81.3 $\pm$ 4.4	75.4 $\pm$ 2.8	< 0.05
Gestational week of delivery	38.3 $\pm$ 4.2	39.9 $\pm$ 1.8	< 0.05
Infant birth weight ,g	2234.6 $\pm$ 275.3	3374.7 $\pm$ 523.4	< 0.05
Number of pregnancies			> 0.05
1	75(70.7)	138(70.8)	
2	29(27.3)	57(29.2)	
Infant sex			> 0.05
Male	63(59.4)	119(61.0)	
Female	43(40.6)	79(39)	
Alcohol intake during pregnancy			> 0.05
No	90(88.8)	159(94.6)	
Yes	16(15.1)	9(5.3)	
Tobacco smoking during pregnancy			> 0.05
Nonsmoker	57(53.7)	97(57.7)	
Passive smoker	46(43.3)	65(38.7)	
Smoker	3(3.0)	6(3.6)	
SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose;HR,heart rate.			

Gene distribution

In this study, the HWE test was used to verify the reliability of the specimen. The results showed that the collected MTHFR C677T, A1298C, and MTRR A66G gene polymorphisms in the population of Northeast China are in line with genetic balance. The data came from the same Mendelian group, and the specimens were regionally representative.

Association between gene polymorphisms and LBW

The genotypic frequencies of MTHFR C677T, A1298C and MTRR A66G were shown in Table 3. MTHFR 677TT and 1298CC genotype were more prevalent in cases than in controls (49.1% vs 29.2%; 13.2% vs 5.3%, respectively). There was significant difference in the distribution of genotype between cases and controls, with ORs of 2.22 (95% CI: 1.14–4.34, $P = 0.02$) and 1.94 (95% CI: 1.66–3.21, $P = 0.01$) for 677TT, when compared with CC and CC + CT, respectively. Similarly, a significant difference in 1298CC genotype distribution were also found between the two study groups, with ORs of 2.82 (95% CI: 1.15–6.87, $P = 0.02$) when compared with AA genotype. The results suggest that MTHFR gene 677TT, 1298CC genotype were associated with an increased risk of LBW. However, none significant result was found in MTRR A66G polymorphism alone.

Table 3
Effects of gene polymorphisms on LBW

Genotype	Cases(N = 106),n (%)	Controls(N = 168),n (%)	OR (95% CI) ^a	P	HWE
MTHFR C677T					0.17
CC	19(12.3)	44(25.0)	Reference		
CT	40(38.6)	75(44.6)	1.24(0.64–2.39)	0.53	
TT	47(49.1)	49(29.2)	2.22(1.14–4.34)	0.02	
CC + CT	59(50.9)	119(70.8)	Reference		
TT	47(49.1)	49(29.2)	1.94(1.66–3.21)	0.01	
MTHFR A1298C					0.12
AA	63(59.4)	114(67.9)	Reference		
AC	29(27.4)	45(26.8)	1.17(0.67–2.04)	0.59	
CC	14(13.2)	9(5.3)	2.82(1.15–6.87)	0.02	
AA	63(59.4)	114(67.9)	Reference		
AC + CC	43(40.6)	54(32.1)	1.44(0.87–2.39)	0.16	
MTRR A66G					0.68
AA	49(46.2)	84(50.0)	Reference		
AG	39(36.8)	68(40.5)	0.98(0.58–1.67)	0.95	
GG	18(17.0)	16(9.5)	1.93(0.90–4.12)	0.09	
AA	49(46.2)	84(50.0)	Reference		
AG + GG	57(71.7)	84(50.0)	1.16(0.72–1.70)	0.54	
^a Adjusted for Maternal age,Height, weight, serum folate,SBP,DBP,FBG,HR,Gestational week of delivery,Infant birth weight.					

Association between genetic interaction and LBW

The joint effects of MTHFR C677T, A1298C and MTRR A66G polymorphisms on LBW were next examined (Table 4). None of the study subjects had the 677TT/1298AC + CC genotypes. When compared with the 677CC + CT/1298AA, the cases with the 677CC + CT/1298AC + CC and 677TT/1298AA genotypes had higher odds of LBW risk (OR = 3.24, 95% CI 1.64–6.37, $p = 0.00$; OR = 3.90, 95% CI 1.98–7.67, $p = 0.00$; repetitively). Moreover, the 677CC + CT/66AG + GG and 677TT/66AG + GG carriers both had higher risks of LBW compared with the reference group (OR = 2.08, 95% CI 1.11–3.93, $p = 0.02$; OR = 7.68, 95% CI 3.43–17.17, $p = 0.00$, repetitively). The trend test was further performed to verify these results, MTHFR C677T/MTHFR C677T and MTHFR C677T/MTRR A66G combinations dramatically increased the LBW risk.

Table 4
Effects of gene-gene interactions on LBW

Genotype 1	Genotype 2	Case/Control	OR (95%CI) ^a	<i>P</i>	<i>P_t</i>
MTHFR C677T	MTHFR A1298C				
CC + CT	AA	16/65	Reference		0.00
CC + CT	AC + CC	43/54	3.24(1.64–6.37)	0.00	
TT	AA	47/49	3.90(1.98–7.67)	0.00	
TT	AC + CC	0/0	-	-	
MTHFR C677T	MTRR A66G				
CC + CT	AA	25/72	Reference		0.00
CC + CT	AG + GG	34/47	2.08(1.11–3.93)	0.02	
TT	AA	15/37	1.17(0.55–2.48)	0.69	
TT	AG + GG	32/12	7.68(3.43–17.17)	0.00	
MTHFR A1298C	MTRR A66G				
AC + CC	AA	22/26	Reference		0.82
AC + CC	AG + GG	21/28	0.89(0.40–1.98)	0.77	
AA	AA	27/58	0.55(0.27–1.14)	0.11	
AA	AG + GG	36/56	0.76(0.38–1.54)	0.45	
^a Adjusted for Maternal age, Height, weight, serum folate, SBP, DBP, FBG, HR, Gestational week of delivery, Infant birth weight.					
<i>P_t</i> : <i>P</i> value of trend test.					

Discussion

LBW is the result of premature delivery and intrauterine growth retardation. At present, the etiology of LBW mainly focuses on maternal diseases and infections, behavioral risk factors and social demographics. Studies at home and abroad have shown that multiple births, insufficient gestational weeks, poor nutrition during pregnancy, history of maternal diseases, umbilical cord abnormalities, history of dysmenorrhea and mental stimulation during pregnancy are risk factors for the occurrence of LBW[17–19]. In view of the importance of genetic factors, a more comprehensive analysis of the risk factors of LBW should be made in conjunction with environmental factors and genetic factors.

As studies have found that hyperHcyemia can induce certain diseases such as congenital malformations and cardiovascular diseases[20–22]. Hcy is a sulfur-containing amino acid whose metabolism is affected by three key enzymes such as MTHFR, as well as folic acid and a variety of vitamins [23]. 5-Methylenetetrahydrofolate is the methyl donor for Hcy methylation. MTHFR plays an important role in the conversion of 5,10-methylenetetrahydrofolate to 5-methylenetetrahydrofolate. Therefore, MTHFR can indirectly regulate the plasma Hcy level [24]. The MTHFR gene C677T can cause the originally synthesized alanine to become valine, thereby reducing the enzyme activity, leading to the hindrance of Hcy metabolism, and which finally causing hyperhomocystinemia (Hhcy)[25]. The maternal blood circulation is connected to the fetus through the placenta. Hhcy will also be manifested in the fetal blood circulation, which can cause fetal blood vessel development abnormalities, neural tube development abnormalities, and premature delivery. This may be one of the reasons for the LBW of the fetus.

After adjusting the confounding factors, our analysis showed that MTHFR 677TT and 1298CC were independently associated with a higher risk of LBW. The MTRR A66G polymorphism was associated with a significant association with LBW when combined with the MTHFR 677TT genotype, but no association was found between LBW and MTRR A66G alone. Moreover, two or more risk genotypes carriers showed higher odds of LBW than null risk genotype one. In line with the above mechanism our data indicate MTHFR 677TT and 1298CC that affects key enzymes in the Hcy metabolic pathway is an independent risk factor for LBW. Additionally, Judging from the results of the interaction analysis, it is suggested that the joint action of multiple gene polymorphisms will increase the risk of LBW.

Conclusions

In conclusion, our study found that maternal MTHFR gene 677TT, 1298CC can increase the risk of LBW in the offspring. The MTRR A66G polymorphism was not associated with LBW alone. But it may exacerbate the effect of the MTHFR C677T variant. Further large prospective population-based studies are required to confirm our findings.

Abbreviations

MTHFR, maternal methylenetetrahydrofolate reductase;LBW,low birth weight;MTRR,Methionine Synthase Reductase;ASPCR, Allele-specific polymerase chain reaction;Hcy,homocysteine;EDTA,ethylenediaminetetraacetic acid;SNPs,single nucleotide polymorphisms;HWE, Hardy–Weinberg equilibrium; SPSS, Statistical Package for the Social Science; ORs, odds ratios; CIs, Hhcy,confidence intervals;hyperhomocystinemia .

Declarations

Supplementary Information

Not applicable

Acknowledgements

Not applicable

Authors'contributions

Shuang Sun and Ying liu contributed to the conception, design and realization of the work. Xuehua Guo and Xun Zhao contributed to the data collection. Shuang Sun contributed to the analysis and drafted the manuscript. All authors read and approved the final manuscript.

Funding

This research was supported by Dean Fund of Jilin Province Maternal and Child Health Hospital.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All procedures conducted in this study involving human participants complied with the ethical standards of the Handbook for Good Clinical Research Practice of the World Health Organization and the Declaration of Helsinki principles (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>). The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Institutional Review Board (IRB) of Maternal and Child Health Hospital of Jilin Province, China. Written informed consent was obtained from all subjects.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Central Laboratory of Maternal and Child Health Hospital of Jilin Province, Changchun 13000,Province, China

References

1. Cai Shixiang. Long-term investigation and analysis of intelligent development and adaptive behavior in low birth weight infants. *Chinese Journal of Eugenics and Genetics*, 2002, 10(1): 91-91.
2. Lin Liangming, Liu Yulin, Zhang Xinli, et al. Results of a sample survey of low birth weight infants in China. *Chinese Journal of Preventive Medicine*, 2002, 36(3): 149-153.
3. PINZON-RODRON A-M, GUTIERREZ-PINZON V, MADRINAN-AVIA H, et al. Low birth weight and prenatal care in Colombia: a cross-sectional study. *Bmc Pregnancy & Childbirth*, 2015, 15(1): 1-7.
4. DORITSAKOU K, LIOSIS G, VALSAMI G, et al. Improved outcomes of feeding low birth weight infants with predominantly raw human milk versus donor banked milk and formula. *J Matern Fetal Neonatal Med*, 2016, 29(7): 1131-1138.
5. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet*, 1995, 10(1): 111-113.
6. Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. *QJM*, 1995, 88(11): 763-766.
7. Frosst P, Blom HJ, Milos R, Goyette P, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet*. 1995;10:111–3.
8. Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. *Atherosclerosis*. 2001;157:451–6.
9. Yi P, Melnyk K, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. *J Biol Chem*. 2000, 38, 29318-29323.
10. Vaughn JD, Bailey LB, Shelnutt KP, Dunwoody KM, Maneval DR, Davis SR, Quinlivan EP, Gregory JF, Kauwell GP. Methionine synthase reductase 66A→G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C→T variant. *J. Nutr*. 2004, 134, 2985–2990.
11. Richter B, Stegmann K, Röper B, Böldcker I, Ngo ET, Koch MC. Interaction of folate and homocysteine pathway genotypes evaluated in susceptibility to neural tube defects (NTD) in a German population. *J Hum Genet*. 2001;46(3):105–9.

12. Chango A, Fillon-Emery N, Mircher C, Bléhaut H, Lambert D, Herbeth B, et al. No association between common polymorphisms in genes of folate and homocysteine metabolism and the risk of Down's syndrome among French mothers. *Br J Nutr.*2005;94:166–9.
13. Van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet.* 1998;62:1044–51.
14. Ueland PM, Rozen R. *MTHFR Polymorphisms and Disease*. 1st ed. Landes Bioscience: Texas; 2005.
15. Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. *Eur J Med Genet* 2015;58:1–0.
16. Yang B, Fan S, Zhi X, et al. Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta-analysis from 114 studies with 15411 cases and 21970 controls. *PLoS One* 2014;9:e87497.
17. Zhang Xinli, Liu Yulin, Lin Liangming, etc. A case-controlled study of risk factors for low birth weight infants in China. *Chinese Journal of Preventive Medicine*, 2002, 36(3): 158-160.
18. Lin Ling, et al. A case-control study on the risk factors of term low birth weight infants in Changning District, Shanghai. *Environmental and Occupational Medicine*, 2008, 25(2): 163-170.
19. Mushy CC, et al. Abuse: a risk factor for low birth weight? A systematic review and meta-analysis. *CMAJ*, 2001, 164(11): 1567.
20. Mills JL, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. *Lancet*, 1995, 345(8943): 149-151.
21. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. *Clinical Chemistry*, 1998, 44(8Pt2): 1833-1843.
22. McCully KS. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. *Clin Chem Lab Med*, 2005, 43(10): 980-986.
23. Du Jingyun, Yang Xinxin, Gong Bo, etc. Correlation between plasma homocysteine, folic acid and MTHFR gene polymorphisms and preterm birth. *Journal of Sun Yat-sen University: Medical Science Edition*, 2013, 34(6): 894-899.
24. Dell'Edera D, L'Episcopia A, Simone F, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms and susceptibility to recurrent pregnancy loss. *Biomed Rep*, 2018, 8(2): 172-175.
25. Wang BJ, Liu MJ, Wang Y, et al. Association between SNPs in genes involved in folate metabolism and preterm birth risk. *Genet Mol Res*, 2015, 14(1): 850-859.